Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial

MLA

Fernando Gomollón, et al. “Efficacy and Safety of Short-Term Adalimumab Treatment in Patients with Active Crohn’s Disease Who Lost Response or Showed Intolerance to Infliximab: A Prospective, Open-Label, Multicentre Trial.” Alimentary Pharmacology & Therapeutics, vol. 25, Jan. 2007, pp. 409–18. EBSCOhost, https://doi.org/10.1111/j.1365-2036.2006.03232.x.

APA

Fernando Gomollón, Guillermo Bastida, M. Penate, S. A. Garcia, Joaquín Hinojosa, D Ceballos, Cristina Saro, José Luis Cabriada, & Miquel A. Gassull. (2007). Efficacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Alimentary Pharmacology & Therapeutics, 25, 409–418. https://doi.org/10.1111/j.1365-2036.2006.03232.x

Chicago

Fernando Gomollón, Guillermo Bastida, M. Penate, S. A. Garcia, Joaquín Hinojosa, D Ceballos, Cristina Saro, José Luis Cabriada, and Miquel A. Gassull. 2007. “Efficacy and Safety of Short-Term Adalimumab Treatment in Patients with Active Crohn’s Disease Who Lost Response or Showed Intolerance to Infliximab: A Prospective, Open-Label, Multicentre Trial.” Alimentary Pharmacology & Therapeutics 25 (January): 409–18. doi:10.1111/j.1365-2036.2006.03232.x.